Company intelligence / Profile preview

Shenzhen Deepin Biotechnology

Shenzhen, Guangdong, Chinaen.genomics.cn ↗

Ownership: Private
Development stage: Other

Overview

Dymind has developed and commercialized a range of automated hematology analyzers and diagnostic platforms used in over 140 countries. Their products are recognized for innovation in automation and high-throughput laboratory solutions. The company invests heavily in R&D (>20% of revenue) and holds numerous national patents. No clinical trial results as they do not develop therapeutics.

Therapeutic areas: OtherImmunologyHematology
Modalities: DeviceReagent (for IVD use)Diagnostic instrument
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Shenzhen Deepin Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Deepin Biotechnology.

Explore the full profile